Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RCT Of Oral Thalidomide And Capecitabine Versus Supportive Therapy In The Treatment Of Unresectable Hepatocellular Carcinoma (BCLC D)

NCT01438450 is registered in ClinicalTrials.gov with All India Institute of Medical Sciences as lead sponsor.

NCT NCT01438450
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01438450 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RCT Of Oral Thalidomide And Capecitabine Versus Supportive Therapy In The Treatment Of Unresectable Hepatocellular Carcinoma (BCLC D)
Lead sponsor
All India Institute of Medical Sciences
Phase
Phase 2/3
Overall status
Unknown status
Start date
October 31, 2007
Completion date
September 30, 2014
Enrollment
74 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma